KR20230088764A - 항her2 항체의 방사성 복합체, 및 방사성 의약 - Google Patents

항her2 항체의 방사성 복합체, 및 방사성 의약 Download PDF

Info

Publication number
KR20230088764A
KR20230088764A KR1020237016275A KR20237016275A KR20230088764A KR 20230088764 A KR20230088764 A KR 20230088764A KR 1020237016275 A KR1020237016275 A KR 1020237016275A KR 20237016275 A KR20237016275 A KR 20237016275A KR 20230088764 A KR20230088764 A KR 20230088764A
Authority
KR
South Korea
Prior art keywords
antibody
complex
group
peptide
chelating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237016275A
Other languages
English (en)
Korean (ko)
Inventor
미노루 가와타니
다카히사 하나다
고타 도노야
다쿠야 다케다
Original Assignee
니혼 메디피직스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니혼 메디피직스 가부시키가이샤 filed Critical 니혼 메디피직스 가부시키가이샤
Publication of KR20230088764A publication Critical patent/KR20230088764A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237016275A 2020-10-16 2021-10-15 항her2 항체의 방사성 복합체, 및 방사성 의약 Pending KR20230088764A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JPJP-P-2020-174840 2020-10-16
JP2020174840 2020-10-16
JP2020215740 2020-12-24
JPJP-P-2020-215740 2020-12-24
JP2021024688 2021-02-18
JPJP-P-2021-024688 2021-02-18
PCT/JP2021/038207 WO2022080481A1 (ja) 2020-10-16 2021-10-15 抗her2抗体の放射性複合体、及び、放射性医薬

Publications (1)

Publication Number Publication Date
KR20230088764A true KR20230088764A (ko) 2023-06-20

Family

ID=81208085

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016275A Pending KR20230088764A (ko) 2020-10-16 2021-10-15 항her2 항체의 방사성 복합체, 및 방사성 의약

Country Status (10)

Country Link
US (1) US20230390425A1 (cg-RX-API-DMAC7.html)
EP (1) EP4230637A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022080481A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230088764A (cg-RX-API-DMAC7.html)
AU (1) AU2021361746A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198721A1 (cg-RX-API-DMAC7.html)
IL (1) IL302111A (cg-RX-API-DMAC7.html)
MX (1) MX2023004428A (cg-RX-API-DMAC7.html)
TW (1) TW202233247A (cg-RX-API-DMAC7.html)
WO (1) WO2022080481A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016186206A1 (ja) 2015-05-20 2016-11-24 国立大学法人鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
WO2017217347A1 (ja) 2016-06-13 2017-12-21 国立大学法人鹿児島大学 IgG結合ペプチドによる部位特異的RI標識抗体
WO2019125982A1 (en) 2017-12-18 2019-06-27 Janssen Biotech, Inc. Radiolabeling of polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
CA3097101A1 (en) * 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
JP2020021574A (ja) 2018-07-30 2020-02-06 パナソニックIpマネジメント株式会社 光源ユニット、照明器具、及び照明器具用の拡張構造
JP2020174840A (ja) 2019-04-17 2020-10-29 豊丸産業株式会社 遊技機
JP7272895B2 (ja) 2019-08-02 2023-05-12 清水建設株式会社 水平搬送台車
PH12022550894A1 (en) * 2019-10-18 2023-03-27 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN114555132A (zh) * 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
JP7680745B2 (ja) 2019-10-24 2025-05-21 国立大学法人 鹿児島大学 1価ccap生成物の製造方法
JP7154465B1 (ja) * 2021-01-08 2022-10-17 日本メジフィジックス株式会社 Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法
JPWO2023033022A1 (cg-RX-API-DMAC7.html) * 2021-08-31 2023-03-09

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016186206A1 (ja) 2015-05-20 2016-11-24 国立大学法人鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
WO2017217347A1 (ja) 2016-06-13 2017-12-21 国立大学法人鹿児島大学 IgG結合ペプチドによる部位特異的RI標識抗体
WO2019125982A1 (en) 2017-12-18 2019-06-27 Janssen Biotech, Inc. Radiolabeling of polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Res. 2003 Aug 15; 63(16): 5084-90
Clin Cancer Res. 2004 Jul 1; 10(13): 4489-97

Also Published As

Publication number Publication date
IL302111A (en) 2023-06-01
JPWO2022080481A1 (cg-RX-API-DMAC7.html) 2022-04-21
CA3198721A1 (en) 2022-04-21
MX2023004428A (es) 2023-05-04
TW202233247A (zh) 2022-09-01
US20230390425A1 (en) 2023-12-07
EP4230637A1 (en) 2023-08-23
AU2021361746A1 (en) 2023-06-22
WO2022080481A1 (ja) 2022-04-21
AU2021361746A9 (en) 2024-06-27
EP4230637A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP7679326B2 (ja) Ri標識されたヒト化抗体
TWI875842B (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
CN118159305A (zh) 脱糖基化抗体的放射性复合物和放射性药物
WO2023277144A1 (ja) Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体
EP4609881A1 (en) Radioactive pharmaceutical composition
CN116456992A (zh) 抗her2抗体的放射性复合物和放射性药物
KR20230174243A (ko) β선을 방출하는 핵종으로 표지된 인간화 항체
US20230390425A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
EP4327831A1 (en) Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
US20250152760A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
US20240207463A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
EA051630B1 (ru) Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство
CN117769440A (zh) 抗cd20抗体的放射性复合物和放射性药物
HK40092772A (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
CN117377690A (zh) 抗egfr抗体的放射性复合物和放射性药物
KR20230174238A (ko) 방사성 항종양제
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241007

Comment text: Request for Examination of Application